Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 692 of 5804
-
New dosing strategy for myeloma drug shows promise in early trial
Disease control CompletedThe purpose of the study (Part 1 and Part 2) is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment or has…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New yellow fever vaccine shows promise in Mid-Stage trial
⭐️ VACCINE ⭐️ OngoingVYF03 is a phase II, randomized, parallel-group prevention study with 2 arms, active-controlled (Stamaril), observer-blind, multi-center study to assess the non-inferiority of the immune response, in terms of seroconversion rates of the investigational vaccine candidate vYF to th…
Phase: PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:01 UTC
-
New shigella vaccine shows promise in first human trials
⭐️ VACCINE ⭐️ CompletedThe aim of the current clinical study was to evaluate, for the first time in humans (FTIH), the safety and immunogenicity of the altSonflex1-2-3 candidate vaccine against S. sonnei and S. flexneri serotypes 1b, 2a, and 3a. The vaccine was first administered to adults 18 to 50 yea…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:01 UTC
-
New drug aims to tame giant cell arteritis with fewer steroids
Disease control CompletedThis is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New combo before lung surgery shows promise in early trial
Disease control Recruiting nowThis single-arm phase 2 study will enroll patients with resectable and operable stage IB - III non-small cell lung cancer and treat them with pre-operative ipilimumab + nivolumab plus low-dose stereotactic body radiation therapy (SBRT) delivered concurrently. Only patients who pr…
Phase: PHASE2 • Sponsor: Brown University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New triple therapy targets Hard-to-Treat cancers
Disease control OngoingBackground: Often, metastatic human papillomavirus (HPV) associated cancers cannot be cured. They also do not respond well to treatment. Some forms of colon cancer also have poor responses to treatment. Researchers want to see if a new drug treatment can help people with these t…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug shows promise in cutting COPD attacks
Disease control CompletedThis study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a history of frequent exacerba…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for kids with MS: drug showdown begins
Disease control OngoingEfficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy aims to boost lymphoma treatment
Disease control OngoingThis phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Start HPV shots at age 9? new study aims to save lives
Prevention CompletedEvery year, thousands of Americans die from cancers related to human papillomavirus (HPV). The vast majority of those deaths could be prevented with a safe and effective vaccine, yet many parents choose not have their children vaccinated when it is recommended at age 11 or 12. In…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Prevention
Last updated Jul 18, 2026 00:00 UTC
-
Zapping resistant tumors with precision radiation may extend the life of current cancer therapy
Disease control Recruiting nowA registry-based randomized phase II trial. A total of 46 patients with metastatic cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, contin…
Phase: PHASE2 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Heart attack drug shows promise for Non-Diabetics
Disease control CompletedThis study will evaluate the effect of ISGLT2 (Dapagliflozin or Empalgliflozin), administered once daily in addition to standard of care treatments for non-diabetic patients with myocardial infarction (MI) treated with PCI, on hospitalization for heart failure, readmissions for a…
Sponsor: Mohammed VI University Hospital • Aim: Disease control
Last updated Jun 26, 2026 17:05 UTC
-
Weight-Loss drug semaglutide may also ease knee pain in obesity
Symptom relief CompletedThis study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Could a special light keep nursing home residents safer from flu and COVID?
Prevention CompletedElderly people who have multiple health problems are at higher risk of illness from viral respiratory infections, such as influenza (the flu) and COVID-19. This is especially true for residents in long-term care because the usual methods of infection control (handwashing, mask-we…
Phase: NA • Sponsor: Kenneth Rockwood • Aim: Prevention
Last updated Jun 27, 2026 08:10 UTC
-
New blood and tissue test could spot High-Risk lung cancer patients early
Diagnosis Recruiting nowLung cancer is the leading cause of cancer mortality worldwide in spite of the advanced progresses in medication and low-dose CT screening. The early-stage lung cancer accounts for less than 50% of newly diagnosed lung cancer in Taiwan, even in stage IB patients proximately 30% s…
Sponsor: Chung Shan Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 09:06 UTC
-
New drug duo aims to outsmart resistant ovarian cancer
Disease control OngoingTo learn if adding etigilimab to nivolumab therapy can help to control clear cell ovarian, fallopian tube, and primary peritoneal cancers that are resistant to platinum-based therapy
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New device sucks out dangerous blood clots in leg veins
Disease control OngoingThe objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment.
Phase: NA • Sponsor: Penumbra Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New imaging agent could spot returning prostate cancer earlier
Diagnosis CompletedThe current study aimed at evaluating the diagnostic performance of \[18F\]CTT1057 as a PET imaging agent for detection and localization of Prostate specific membrane antigen (PSMA) positivity in patients diagnosed of biochemical recurrence of prostate cancer (PCa), using a compo…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Jun 27, 2026 07:55 UTC
-
Glowing dye could help surgeons spot hidden brain tumor cells
Diagnosis CompletedThe purpose of this study is to examine the use of a single dose of tozuleristide (24 or 36 mg) and the Canvas imaging system during surgical resection of primary central nervous system (CNS) tumors: Primary gadolinium enhancing (high grade) CNS tumors, primary non-gadolinium enh…
Phase: PHASE2 • Sponsor: John Yu • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
New drug duo targets lung cancer brain metastases
Disease control CompletedThe researchers think that the study drugs, amivantamab and lazertinib, may be an effective treatment for people who have metastatic NSCLC with an EGFR mutation. Both drugs work to target cancer cells with an EGFR mutation, and this targeting action could stop or slow the growth …
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC